Erratum: Baseline serum albumin is a predictive biomarker for patients with advanced pancreatic cancer treated with bevacizumab: A pooled analysis of 7 prospective trials of gemcitabine-based therapy with or without bevacizumab. (Cancer 2014 120 (1780-1786))
Journal article published in 2015 by
S. Pant,
L. K. Martin,
S. Geyer,
L. Wei 
,
K. Van Loon,
N. Sommovilla,
M. Zalupski,
R. Iyer,
D. Fogelman,
A. H. Ko,
T. Bekaii-Saab
,
K. Van Loon,
N. Sommovilla,
M. Zalupski,
R. Iyer,
D. Fogelman,
A. H. Ko,
T. Bekaii-Saab
